指南与共识关节外科

2017年美国风湿病学会/美国髋膝关节外科医师协会指南:风湿病患者接受择期全髋或全膝关节置换术时抗风湿药物的围手术期管理

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
指南 / 共识 · J Arthroplasty · 2017-06-16

该指南由美国风湿病学会与美国髋膝关节外科医师协会合作制定,针对类风湿关节炎、脊柱关节炎(含强直性脊柱炎和银屑病关节炎)、幼年特发性关节炎或系统性红斑狼疮的成人患者,在择期全髋或全膝关节置换术前后的抗风湿药物管理提供循证推荐。指南共给出7条推荐,均为条件性推荐,基于低或中等质量证据,涉及传统改善病情抗风湿药、生物制剂、托法替布和糖皮质激素的继续、停用与重启时机及围手术期激素最优剂量。

要点

  • 指南涵盖类风湿关节炎、脊柱关节炎、幼年特发性关节炎和系统性红斑狼疮成人患者择期全髋或全膝关节置换的围手术期抗风湿药物管理。
  • 共7条推荐,均为条件性推荐,基于低或中等质量证据。
  • 推荐涉及传统改善病情抗风湿药、生物制剂、托法替布和糖皮质激素的继续、停用与重启时机及激素围手术期最优剂量。

核心结论

  • 该指南应有助于临床医生和患者就择期全髋或全膝关节置换时围手术期抗风湿药物管理作出决策。
  • 这些条件性推荐反映了缺乏高质量的直接随机对照试验数据。

研究设计与样本

  • 由美国风湿病学会与美国髋膝关节外科医师协会合作,召集风湿病学家、专攻髋膝关节置换的骨科外科医生和方法学家组成专家组构建关键临床问题。
  • 随后进行多步骤系统文献综述,合成继续与停用抗风湿药物以及围手术期糖皮质激素优化管理的证据。
  • 召集患者小组确定患者价值观与偏好,采用推荐分级的评估、制定与评价(GRADE)方法学,通过风湿病学家和骨科外科医生组成的投票小组进行群体共识流程,评定证据质量和推荐强度。

主要发现

  • 指南涉及类风湿关节炎、脊柱关节炎、幼年特发性关节炎或系统性红斑狼疮成人患者择期全髋或全膝关节置换时传统改善病情抗风湿药、生物制剂、托法替布和糖皮质激素的围手术期使用。
  • 指南提供关于何时继续、何时停用、何时重启这些药物以及围手术期糖皮质激素最优剂量的推荐。
  • 指南包括7条推荐,所有推荐均为条件性推荐,基于低或中等质量证据。

关键数值与推荐

  • 推荐强度反映在考虑现有证据质量和患者价值观与偏好变异性的情况下,受益大于伤害或伤害大于受益的确定程度。
  • 指南包括7条推荐,均为条件性推荐,基于低或中等质量证据。

临床怎么用

  • 该指南应有助于临床医生和患者就择期全髋或全膝关节置换时围手术期抗风湿药物管理作出决策。

局限性

  • 这些条件性推荐反映了缺乏高质量的直接随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). METHODS: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. RESULTS: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. CONCLUSION: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017. PMID: 28629905. doi:10.1016/j.arth.2017.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。